1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
490.72%
Cash & equivalents yoy growth at least 1.5x the Drug Manufacturers - Specialty & Generic median of 1.08%. Joel Greenblatt might see strong liquidity accumulation as an advantage. Check if management invests or just hoards cash.
-12.95%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-9.37%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.11%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-9.52%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-9.38%
Below half the Drug Manufacturers - Specialty & Generic median of 0.79%. Jim Chanos would question if the company faces working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.38%
Below half the Drug Manufacturers - Specialty & Generic median of 0.41%. Jim Chanos might see potential stagnation or distress vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
434.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.27%. Jim Chanos suspects a potential short-term burden spike.
434.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 6.49%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
434.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.49%. Jim Chanos suspects an alarming rise in overall leverage.
-4.58%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-29.73%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-22.07%
Below half Drug Manufacturers - Specialty & Generic median of 0.91%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-9.38%
Below half Drug Manufacturers - Specialty & Generic median of 0.41%. Jim Chanos suspects a major slowdown or distress.
-12.95%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-490.72%
Above 1.5x Drug Manufacturers - Specialty & Generic median -0.34%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
